

Pharmacy BULLETIN BOARD

Industry Issue ■ Monday May 11, 2015

Odan Laboratories is pleased to introduce their new sodium chloride product:

ODAN-SODIUM CHLORIDE

OPHTHALMIC OINTMENT USP

Odan-Sodium Chloride™ ophthalmic ointment is indicated for the temporary relief of corneal edema

The only equivalent to Muro-128[†]

Product	Format	Odan	K & F	McKesson
Odan-Sodium Chloride Ointment NPN 80046696	3.5 g	12735	149285	067490
Odan-Sodium Chloride Solution* NPN 80046737	15 mL	12515	149153	067456

*Covered by the British-Columbia formulary

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at info@odanlab.com.



*Odan Laboratories Ltd., Montreal, QC, Canada H9R 2Y6
[†]Muro 128 is a registered trademark of Bausch & Lomb

■ FROM THE NEWSWIRE ■

OTTAWA: Health Canada is working with the Canadian manufacturers of prescription oral ibuprofen products to update the safety information regarding the risk of serious cardiovascular side effects (e.g., heart attack and stroke) when these products are used at high doses (at 2400 mg/day). This risk increases with dose and duration of use.

QUÉBEC CITY: Aeterna Zentaris Inc. has announced that the independent Data Safety Monitoring Board ("DSMB") for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, has completed a pre specified first interim futility analysis. The DSMB has recommended that the Phase 3 study continue as planned.

MISSISSAUGA: People with HER2-positive metastatic breast cancer in Prince Edward Island (P.E.I.) will now be able to access a new treatment option through the P.E.I. Pharmacare Formulary. Pertuzumab (PER-JETA®) and trastuzumab (HERCEPTIN®) have been approved for use in combination with a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within six months of receiving trastuzumab in the adjuvant setting.

CAMBRIDGE, Mass.: Biogen has announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis (MS). Data show TECFIDERA significantly reduced relapses and disability progression in newly-diagnosed relapsing-remitting MS (RRMS) patients who had highly active disease. Additional data indicate TECFIDERA showed strong and sustained efficacy over five years in RRMS patients who were previously treated with an interferon (interferon beta-1a/b [IFN]) or glatiramer acetate (GA).

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 |
hrc@healthresponse.ca

Next Issue: Monday May 25th, 2015
 Deadline: Thursday May 21st, 2015